Page 116 - 南京医科大学学报自然科学版
P. 116
第43卷第4期
·554 · 南 京 医 科 大 学 学 报 2023年4月
cell lung cancer[J]. N Engl J Med,2015,373(2):123- [11] GAO F,YANG C. Anti⁃VEGF/VEGFR2 monoclonal anti⁃
135 bodies and their combinations with PD⁃1/PD⁃L1 inhibi⁃
[3] RECK M,BRAHMER J,BENNETT B,et al. Evaluation tors in clinic[J]. Curr Cancer Drug Targets,2020,20(1):
of health⁃related quality of life and symptoms in patients 3-18
with advanced non⁃squamous non⁃small cell lung cancer [12] 王梦玮,徐天蔚,王朝霞. PD⁃1/PD⁃L1免疫检查点抑制
treated with nivolumab or docetaxel in CheckMate 057 剂在肺癌临床研究中的进展[J]. 南京医科大学学报
[J]. Eur J Cancer,2018,102:23-30 (自然科学版),2021,41(7):1084-1094
[4] CHANG J,WU Y L,LU S,et al. Three⁃year follow⁃up and [13] YANG J,YAN J,LIU B. Targeting VEGF/VEGFR to mod⁃
patient⁃reported outcomes from CheckMate 078:Nivolum⁃ ulate antitumor immunity[J]. Front Immunol,2018,9:
ab versus docetaxel in a predominantly Chinese patient 978
population with previously treated advanced non ⁃ small [14] YANG Y,LI L,JIANG Z,et al. Anlotinib optimizes anti⁃
cell lung cancer[J]. Lung Cancer,2021,165:71-81 tumor innate immunity to potentiate the therapeutic effect
[5] FEHRENBACHER L,VON PAWEL J,PARK K,et al. of PD⁃1 blockade in lung cancer[J]. Cancer Immunol Im⁃
Updated efficacy analysis including secondary population munother,2020,69(12):2523-2532
results for OAK:a randomized phase Ⅲ study of atezoli⁃ [15] ZHANG C,ZHANG J,TAN J,et al. Cost⁃effectiveness of
zumab versus docetaxel in patients with previously treat⁃ pembrolizumab for the treatment of non⁃small⁃cell lung
ed advanced non⁃small cell lung cancer[J]. J Thorac On⁃ cancer:a systematic review[J]. Front Oncol,2022,12:
col,2018,13(8):1156-1170 815587
[6] HEGDE P S,WALLIN J J,MANCAO C. Predictive mark⁃ [16] LIU S,QIN T,LIU Z,et al. anlotinib alters tumor immune
ers of anti⁃VEGF and emerging role of angiogenesis inhib⁃ microenvironment by downregulating PD ⁃ L1 expression
itors as immunotherapeutics[J]. Semin Cancer Biol, on vascular endothelial cells[J]. Cell Death Dis,2020,11
2018,52(2):117-124 (5):309
[7] CAI X,WEI B,LI L,et al. Apatinib enhanced anti⁃PD⁃1 [17] KOHEI S,MEENAL D,TAI H,et al. Dual programmed
therapy for colon cancer in mice via promoting PD⁃L1 ex⁃ death receptor ⁃ 1 and vascular endothelial growth factor
pression[J]. Int Immunopharmacol,2020,88:106858 receptor⁃2 blockade promotes vascular normalization and
[8] HUANG Y,KIM B Y S,CHAN C K,et al. Improving im⁃ enhances antitumor immune responses in hepatocellular
mune ⁃ vascular crosstalk for cancer immunotherapy[J]. carcinoma[J]. Hepatol Baltim Md,2020,71(4):1247-
Nat Rev Immunol,2018,18(3):195-203 1261
[9] TERME M,PERNOT S,MARCHETEAU E,et al. VEGFA⁃ [18] GONZALEZ H,HAGERLING C,WERB Z. Roles of the
VEGFR pathway blockade inhibits tumor⁃induced regula⁃ immune system in cancer:from tumor initiation to meta⁃
tory T⁃cell proliferation in colorectal cancer[J]. Cancer static progression[J]. Genes Dev,2018,32(19/20):
Res,2013,73(2):539-549 1267-1284
+
[10] HAN B,LI K,WANG Q,et al. Effect of anlotinib as a [19] BORST J,AHRENDS T,BABAŁA N,et al. CD4 T cell
third⁃Line or further treatment on overall survival of pa⁃ help in cancer immunology and immunotherapy[J]. Nat
tients with advanced non⁃small cell lung cancer:the AL⁃ Rev Immunol,2018,18(10):635-647
TER 0303 phase 3 randomized clinical trial[J]. JAMA [收稿日期] 2022-04-21
Oncol,2018,4(11):1569-1575 (责任编辑:蒋 莉)